Fujino, Masahiko
Takeda Pharmaceutical Company Limited,
Japan
2024 Rank: 96894
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Biomedical Research
SubField 1:
Biochemistry & Molecular Biology
SubField 2:
General Chemistry
Rank in SubField 1: 3748 out of 208384 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 96894 | 109633 |
| Total Cites | 18104 | 19066 |
| H-index | 63 | 64 |
| Hm-index | 15 | 16 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 13 | 13 |
| Number of Single+First Authored Papers | 42 | 42 |
| Total Cites to Single+First Authored Papers | 314 | 320 |
| Number of Single+First+Last Authored Papers | 206 | 206 |
| Total Cites to Single+First+Last Authored Papers | 15424 | 16120 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 13086 | 13382 |
| Ratio of Total Citations to Distinct Citing Papers | 1.38 | 1.42 |
| Self-Citation Percentage |
5.05%
|
|
Fujino, Masahiko
Japanese Red Cross Nagoya Daiichi Hospital,
Japan
2023 Rank: 86446
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Biochemistry & Molecular Biology
SubField 2:
General Chemistry
Rank in SubField 1: 3518 out of 204091 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 86446 | 98007 |
| Total Cites | 17882 | 18876 |
| H-index | 62 | 64 |
| Hm-index | 16 | 17 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 13 | 13 |
| Number of Single+First Authored Papers | 44 | 44 |
| Total Cites to Single+First Authored Papers | 327 | 338 |
| Number of Single+First+Last Authored Papers | 233 | 233 |
| Total Cites to Single+First+Last Authored Papers | 15015 | 15719 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 12941 | 13260 |
| Ratio of Total Citations to Distinct Citing Papers | 1.38 | 1.42 |
| Self-Citation Percentage |
5.27%
|
|
Fujino, Masahiko
Harvard Medical School,
United States
2022 Rank: 84498
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Biomedical Research
SubField 1:
Biochemistry & Molecular Biology
SubField 2:
General Chemistry
Rank in SubField 1: 3576 out of 201173 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 84498 | 95815 |
| Total Cites | 16892 | 17852 |
| H-index | 62 | 64 |
| Hm-index | 15 | 16 |
| Number of Single Authored Papers | 4 | 4 |
| Total Cites to Single Authored Papers | 12 | 12 |
| Number of Single+First Authored Papers | 43 | 43 |
| Total Cites to Single+First Authored Papers | 286 | 294 |
| Number of Single+First+Last Authored Papers | 208 | 208 |
| Total Cites to Single+First+Last Authored Papers | 14318 | 15017 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 12085 | 12377 |
| Ratio of Total Citations to Distinct Citing Papers | 1.40 | 1.44 |
| Self-Citation Percentage |
5.38%
|
|
Fujino, Masahiko
Harvard Medical School,
United States
2020 Rank: 72864
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Biomedical Research
SubField 1:
Biochemistry & Molecular Biology
SubField 2:
Endocrinology & Metabolism
Rank in SubField 1: 2724 out of 135836 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 72864 | 83040 |
| Total Cites | 15744 | 16698 |
| H-index | 61 | 64 |
| Hm-index | 15 | 16 |
| Number of Single Authored Papers | 3 | 3 |
| Total Cites to Single Authored Papers | 12 | 12 |
| Number of Single+First Authored Papers | 42 | 42 |
| Total Cites to Single+First Authored Papers | 268 | 276 |
| Number of Single+First+Last Authored Papers | 205 | 205 |
| Total Cites to Single+First+Last Authored Papers | 13317 | 14013 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 11142 | 11431 |
| Ratio of Total Citations to Distinct Citing Papers | 1.41 | 1.46 |
| Self-Citation Percentage |
5.71%
|
|